Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis.

@article{McCoy2003DrotrecoginA,
  title={Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis.},
  author={Christopher M McCoy and S. J. Matthews},
  journal={Clinical therapeutics},
  year={2003},
  volume={25 2},
  pages={
          396-421
        }
}
BACKGROUND The search for a life-preserving drug to treat sepsis has increased understanding of the pathogenesis of the process but produced little in the way of successful treatments. The prospective, randomized, double-blind, placebo-controlled, Phase III, multicenter Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial suggested that drotrecogin alfa--recombinant human activated protein C--significantly improved 28-day mortality rates in acute sepsis (P… Expand
Human recombinant activated protein C for severe sepsis.
Drotrecogin Alfa (Activated)
Human recombinant activated protein C for severe sepsis.
Use of drotrecogin alfa (activated) for severe sepsis in New Jersey acute care hospitals.
Adjuvant therapy for meningococcal sepsis.
'Role reversal' for the receptor PAR1 in sepsis-induced vascular damage
...
1
2
3
...

References

SHOWING 1-10 OF 74 REFERENCES
Clinical trials of immunomodulatory therapies in severe sepsis and septic shock.
...
1
2
3
4
5
...